FDA Guides Waivers for pH Tweaks in Eye and Ear Drugs
Published Date: 11/17/2025
Notice
Summary
The FDA just released new guidance to help companies making generic injectable, eye, or ear medicines when they want to change the pH adjusters from the original drug. This makes it clearer how to ask for permission to use different pH adjusters, speeding up approvals and possibly saving money. The guidance is effective starting November 17, 2025, so drug makers should get ready to follow these new rules.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
How to Request pH Adjuster Waivers
If you make generic injectable (parenteral), eye (ophthalmic), or ear (otic) medicines and want to use pH adjusters that are qualitatively (Q1) or quantitatively (Q2) different from the reference listed drug, this guidance explains how FDA will evaluate a waiver request under Sec. 314.99(b). It describes the types of information applicants should consider submitting and the recommended format and process for submitting such waiver requests.
FDA Feedback Recommended Before Filing
The final guidance includes recommendations that ANDA applicants seek FDA feedback on a proposed approach for justifying a Sec. 314.99(b) waiver for a pH adjuster difference. It also recommends seeking FDA input where the applicant plans to use a particular bioequivalence approach with a formulation that contains a Q1 or Q2 pH adjuster difference.
Confidentiality of Formulation Questions Clarified
The guidance clarifies FDA's obligations to maintain the confidentiality of trade secret and confidential commercial information when FDA responds to questions about drug product formulations. Applicants can expect FDA to distinguish protected confidential information in its communications about formulations.
Guidance Finalized and Published
FDA finalized the guidance titled 'Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use' and published the announcement in the Federal Register on November 17, 2025. The final guidance supersedes the draft issued April 14, 2022.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-19988 — EPA Determinations of Compliance and Applicability Under Clean Air Act Section 111, 112, and 129 Dashboard: EPA Formal Responses to Inquiries Concerning Compliance With the Clean Air Act Stationary Source Program (Since May 2019)
The EPA has made it easier for businesses and facilities to understand if they’re following air pollution rules under the Clean Air Act. Since May 2019, the EPA has shared clear answers about what counts as new or changed pollution sources and how to monitor them. This helps companies avoid fines and plan ahead, saving time and money while keeping our air cleaner.
Next: 2025-19991 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Title-Certification of Qualifying State Relief From Disabilities Program-ATF Form 3210.12
The ATF is updating a form that helps states certify when someone’s gun rights are restored after a disability. This affects people involved in state relief programs and aims to make the process clearer and easier, with a 30-day comment period ending December 17, 2025. No big costs are expected, but your feedback can help improve the form and reduce hassle.